R&D World: Why Precigenetics Aims to Swap Cell 'Autopsies' for Live-Cell Measurement

R&D World senior editor Brian Buntz published a deep dive on Precigenetics and our mission to replace destructive cell measurement with continuous, label-free observation of living biology. The piece centers on a question our founder and CEO Parmita Mishra returns to often: we have rovers on Mars and the James Webb Space Telescope, yet biology is still bottlenecked by measurement tools that kill the sample.

Some highlights from the article:

• Why most high-dimensional methods in cell profiling are inherently destructive, and what that means for understanding drug response, resistance, and toxicity
• How our system keeps cells alive in what the company calls an artificial lung — physiological temperature and 5% CO₂ delivered through microfluidics — while semiconductor-grade optics image them continuously
• The data architecture: full-spectrum hyperspectral measurement generating roughly two to three gigabytes per cell every two hours
• The case for a telescope for understanding living systems, and why drug discovery needs the same engineering step-change that once transformed sequencing
• How the FDA Modernization Act 2.0 and the agency's recent moves on new approach methodologies are reshaping which disease areas and target classes are worth pursuing
• An introduction to Cleopatra, the toxicity foundation model we are building

Read the full article on R&D World